Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released today as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.
“In terms of pharma & biotech share prices, the volatility of 2016 and the unpredictability President Trump has so far displayed will do little to calm industry nerves. Investors and companies might want to brace themselves for these stormy waters to become the new normal this year. Alongside the political landscape, high drug prices will remain the sector’s gremlin in 2017,” said Amy Brown, Pharma & Biotech report author.
“In the medtech sphere the venture funding climate is getting deeper into an endless winter,” said report author Elizabeth Cairns. “While there are some rich rounds, even in the early stages, most companies are struggling to find growth capital.”
Other key findings include:
The two reports published today offer analysis and expert commentary on M&A deals venture financing, initial public offerings and FDA approvals in the pharma and medtech sectors during 2016. The reports are based on EvaluatePharma® and EvaluateMedTech® data. To download the complimentary Pharma & Biotech 2016 in Review report, please visit www.evaluategroup.com/PharmaBiotech2016Review. For the Medtech 2016 in Review report, please visit www.evaluategroup.com/Medtech2016Review.
Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries.
Our EvaluatePharma® online subscription services provides a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.
Vantage – our award-winning, independent editorial team – provide thought-provoking news and insights into the current and future developments in the industry.
Evaluate has been a trusted partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.